The Diagnostic Value of PET/CT in Breast Cancer Recurrence and Metastases
Kh., T., S, A., G, M., G, A., A, A. (2017). The Diagnostic Value of PET/CT in Breast Cancer Recurrence and Metastases. EKB Journal Management System, 15(15), 37-51. doi: 10.21608/egyjnm.2017.46222
Taalab, Kh.; Abutaleb, A S; Moftah, S G; Abdel-Mutaleb, M G; Abdl-Mawla, Y A. "The Diagnostic Value of PET/CT in Breast Cancer Recurrence and Metastases". EKB Journal Management System, 15, 15, 2017, 37-51. doi: 10.21608/egyjnm.2017.46222
Kh., T., S, A., G, M., G, A., A, A. (2017). 'The Diagnostic Value of PET/CT in Breast Cancer Recurrence and Metastases', EKB Journal Management System, 15(15), pp. 37-51. doi: 10.21608/egyjnm.2017.46222
Kh., T., S, A., G, M., G, A., A, A. The Diagnostic Value of PET/CT in Breast Cancer Recurrence and Metastases. EKB Journal Management System, 2017; 15(15): 37-51. doi: 10.21608/egyjnm.2017.46222

The Diagnostic Value of PET/CT in Breast Cancer Recurrence and Metastases

Egyptian Journal Nuclear Medicine
Article 4, Volume 15, Issue 15, December 2017, Page 37-51  XML PDF (393.63 K)
Document Type: Original Article
DOI: 10.21608/egyjnm.2017.46222
View on SCiNiTO View on SCiNiTO
Authors
Taalab, Kh.1; Abutaleb, A S2; Moftah, S G3; Abdel-Mutaleb, M G3; Abdl-Mawla, Y A3
1Military Medical Academy. Egypt.
2Military Medical Academy, Egypt.
3Radiology, Ain Shams University, Egypt.
Abstract
After initial treatment of breast cancer; localization of metastases or recurrences remains a serious challenge that requiring an extensive diagnostic workup. Current literature states that FDG PET/CT should be the first whole-body imaging modality used for restaging in breast cancer patients who are suspected of having disease recurrence. Aim of the work: We aim in our study to highlight the value of PET/CT in diagnosis of local recurrence and/or metastasis in breast cancer. Patients and Methods: We performed whole body 18F FDG-PET/CT on 37 breast carcinoma patients, regardless the pathological subtypes, presenting with clinical, laboratory and/or radiological suspicion of loco-regional or distant metastatic recurrence.
Recurrence is defined as evidence of recurrent lesions within 6 months of the FDG-PET/CT based on conventional imaging techniques, pathology, or clinical follow-up.
Results: A total of thirty seven patients eliciting eighty eight suspicious lesions were evaluated. The overall sensitivity, specificity and accuracy of FDG-PET/CT in our study are 98.65%, 85.71% and 96.59%; the results provide supportive evidence for a role of 18F-FDG PET/CT in determining the stage of disease for high- and intermediate-risk patients. Conclusion: Our results indicated that PET/CT is the most sensitive and accurate tool for follow-up of breast cancer patients presenting with clinical, laboratory and/or radiologic suspicion of loco-regional ordistant metastatic recurrence, hence; FDG-PET/CT should be used as a first priority in patients with steadily rising serum CA15-3 levels, or with clinical/ radiologic suspicion of recurrence.
Keywords
Breast Ca. recurrence; breast cancer metastases; 18F FDG-PET/CT
Statistics
Article View: 151
PDF Download: 463